Biomarkers in early clinical trials: The committed and the skeptics

Clinical Cancer Research

Volumn 14, Issue 8, 2008, Pages 2512-

  Banerji, Udai ^a,b   De Bono, Johann ^a,b   Judson, Ian ^a,b   Kaye, Stanley ^a,b   Workman, Paul ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

KU 0059436; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TANESPIMYCIN; TUMOR MARKER; UNCLASSIFIED DRUG;

CANCER PATIENT; CLINICAL DECISION MAKING; CLINICAL TRIAL; DISEASE MARKER; DRUG TARGETING; GENE MUTATION; HEALTH CARE COST; HUMAN; LETTER; PRIORITY JOURNAL; TUMOR BIOPSY;

CLINICAL TRIALS, PHASE I AS TOPIC; HUMANS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 42249087304     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-5224     Document Type: Letter

References (7)

1. Goulart BHL, Clark JW, Pien HH, et al. Trends in the use and role of biomarkers in phase I oncology trials. Clin Cancer Res 2007;13:6719-26.
2. Ratain MJ, Glassman RH. Biomarkers in phase I oncology trials: signal, noise, or expensive distraction? Clin Cancer Res 2007;13:6545-8.
3. Sarker D, Workman P. Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv Cancer Res 2007;96:213-68.
4. DiMasi JA, Grabowski HG. Economics of new oncology drug development. J Clin Oncol 2007;25:209-16.
5. Yap T, Boss D, Fong P, et al. First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436, a small molecule inhibitor of poly-ADP-ribose polymerase (PARP) in cancer patients, including BRCA 1/2 mutation carriers. J Clin Oncol ASCO Annu Meet Proc 2007;25:3529.
6. Banerji U, O'Donnell A, Scurr M, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23:4152-61.
7. Dowlati A, Haaga J, Remick SC, et al. Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation. Clin Cancer Res 2001;7:2971-6.